Is Shared Decision Making in Prostate Cancer Restrained by Evidence-Based Medicine?  Jacques Irani  European Urology Supplements  Volume 9, Issue 11, Pages 782-787 (December 2010) DOI: 10.1016/j.eursup.2010.11.002 Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 1 Incidence of biopsy-detected prostate cancer in the Prostate Cancer Prevention Trial (PCPT) study at 7 yr and the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study at 4 yr; relative risk reduction (RR) indicated [10,11]. European Urology Supplements 2010 9, 782-787DOI: (10.1016/j.eursup.2010.11.002) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 2 Point incidence of prostate cancer at 12 mo in patients with high-grade prostatic intraepithelial neoplasia treated daily with 20, 40, or 60mg toremifene or placebo. Significant reduction with the 20-mg dose compared with placebo (p=0.045). Reproduced with permission from Price et al [15]. European Urology Supplements 2010 9, 782-787DOI: (10.1016/j.eursup.2010.11.002) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 3 Overall survival in patients with T3/4 M0 or M1 prostate cancer treated with androgen-deprivation therapy on an intermittent or continuous basis. The number of patients still in active follow-up is indicated. Reproduced with the permission from Calais da Silva et al [31]. European Urology Supplements 2010 9, 782-787DOI: (10.1016/j.eursup.2010.11.002) Copyright © 2010 European Association of Urology Terms and Conditions

Fig. 4 Outcome of a patient questionnaire on the preferred type of decision making in men with prostate cancer (n=100) Reproduced with permission from Wong et al [34]. European Urology Supplements 2010 9, 782-787DOI: (10.1016/j.eursup.2010.11.002) Copyright © 2010 European Association of Urology Terms and Conditions